title: Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc.
abstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. It specifically inhibits the replication of R5 viruses by blocking viral entry. HIV-1 tropism can be estimated accurately and predict viral response to maraviroc. Genotypic tools are increasingly replacing phenotypic assays in most places. The favorable pharmacokinetic properties and the good safety profile of maraviroc may support an earlier use of the drug in HIV-1 infection, as well as favor its consideration as part of switch strategies in patients under suppressive antiret-roviral regimens containing less-well-tolerated drugs. Moreover, a particular immune benefit of maraviroc might encourage its use as part of intensification strategies in HIV-infected patients with impaired CD4 gains despite prolonged suppression of HIV replication with antiretroviral therapy. However, the long-term consequences of using maraviroc must be carefully checked, given its particular mechanism of action, blocking a physiologic cell receptor.
authors.affiliation: Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
references.citation: J Clin Microbiol. 2008 Mar;46(3):887-91
references.pmid: 18199789
references.citation: J Infect Dis. 2005 Aug 1;192(3):466-74
references.pmid: 15995960
references.citation: Antivir Ther. 2006;11(6):729-40
references.pmid: 17310817
references.citation: AIDS. 2006 Jun 26;20(10):1359-67
references.pmid: 16791010
references.citation: AIDS Rev. 2003 Apr-Jun;5(2):104-12
references.pmid: 12876899
references.citation: N Engl J Med. 2008 Oct 2;359(14):1429-41
references.pmid: 18832244
references.citation: J Antimicrob Chemother. 2006 Apr;57(4):619-27
references.pmid: 16464888
references.citation: Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32
references.pmid: 16251317
references.citation: Lancet. 2008 Apr 26;371(9622):1417-26
references.pmid: 18387667
references.citation: Nat Med. 2005 Nov;11(11):1170-2
references.pmid: 16205738
references.citation: J Antimicrob Chemother. 2006 Oct;58(4):714-22
references.pmid: 16891628
references.citation: AIDS. 2009 Apr 27;23(7):869
references.pmid: 19363332
references.citation: J Virol. 1999 Mar;73(3):2350-8
references.pmid: 9971818
references.citation: Lancet. 2007 Jul 7;370(9581):81-8
references.pmid: 17617275
references.citation: J Virol. 1999 Aug;73(8):6271-81
references.pmid: 10400718
references.citation: PLoS One. 2009 May 25;4(5):e5683
references.pmid: 19479085
references.citation: N Engl J Med. 2008 Oct 2;359(14):1442-55
references.pmid: 18832245
references.citation: Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
references.pmid: 12019106
references.citation: J Infect Dis. 2009 Jun 1;199(11):1638-47
references.pmid: 19432546
references.citation: J Med Virol. 2004 Sep;74(1):21-8
references.pmid: 15258964
references.citation: AIDS. 2009 Jun 19;23(10):1209-18
references.pmid: 19424056
references.citation: Antivir Ther. 2009;14(5):607-18
references.pmid: 19704163
references.citation: AIDS Patient Care STDS. 2007 Sep;21(9):702
references.pmid: 17919097
references.citation: AIDS Rev. 2009 Jan-Mar;11(1):30-8
references.pmid: 19290032
references.citation: J Antimicrob Chemother. 2009 Jun;63(6):1087-96
references.pmid: 19377064
references.citation: AIDS. 2007 Jul 11;21(11):1487-90
references.pmid: 17589199
references.citation: Antimicrob Agents Chemother. 2007 Feb;51(2):566-75
references.pmid: 17116663
references.citation: AIDS. 2008 Sep 12;22(14):F11-6
references.pmid: 18753930
references.citation: Biochemistry. 2003 Feb 18;42(6):1544-50
references.pmid: 12578367
references.citation: AIDS. 2009 Sep 10;23(14):1911-3
references.pmid: 19584703
references.citation: AIDS. 2007 Sep 12;21(14):F17-24
references.pmid: 17721088
references.citation: J Virol. 2002 Sep;76(17):8953-7
references.pmid: 12163614
references.citation: Curr Diab Rep. 2009 Feb;9(1):37-42
references.pmid: 19192423
references.citation: J Antimicrob Chemother. 2009 May;63(5):1006-10
references.pmid: 19261623
references.citation: Nature. 1998 Jan 15;391(6664):240
references.pmid: 9440686
references.citation: J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):241-4
references.pmid: 18545159
references.citation: AIDS. 2008 Jan 2;22(1):1-13
references.pmid: 18090386
references.citation: AIDS Rev. 2005 Jul-Sep;7(3):139-47
references.pmid: 16302461
references.citation: Curr Opin HIV AIDS. 2009 Mar;4(2):136-42
references.pmid: 19339953
references.citation: Nat Biotechnol. 2003 May;21(5):470-1
references.pmid: 12721558